These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 28376279)

  • 1. Molecular mechanisms underlying protective effects of quercetin against mitochondrial dysfunction and progressive dopaminergic neurodegeneration in cell culture and MitoPark transgenic mouse models of Parkinson's Disease.
    Ay M; Luo J; Langley M; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
    J Neurochem; 2017 Jun; 141(5):766-782. PubMed ID: 28376279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mito-metformin protects against mitochondrial dysfunction and dopaminergic neuronal degeneration by activating upstream PKD1 signaling in cell culture and MitoPark animal models of Parkinson's disease.
    Ay M; Charli A; Langley M; Jang A; Padhi P; Jin H; Anantharam V; Kalyanaraman B; Kanthasamy A; Kanthasamy AG
    Front Neurosci; 2024; 18():1356703. PubMed ID: 38449738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopaminergic Neurons Exhibit an Age-Dependent Decline in Electrophysiological Parameters in the MitoPark Mouse Model of Parkinson's Disease.
    Branch SY; Chen C; Sharma R; Lechleiter JD; Li S; Beckstead MJ
    J Neurosci; 2016 Apr; 36(14):4026-37. PubMed ID: 27053209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The MitoPark Mouse - an animal model of Parkinson's disease with impaired respiratory chain function in dopamine neurons.
    Ekstrand MI; Galter D
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S185-8. PubMed ID: 20082987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Manganese exposure exacerbates progressive motor deficits and neurodegeneration in the MitoPark mouse model of Parkinson's disease: Relevance to gene and environment interactions in metal neurotoxicity.
    Langley MR; Ghaisas S; Ay M; Luo J; Palanisamy BN; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
    Neurotoxicology; 2018 Jan; 64():240-255. PubMed ID: 28595911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of nonmotor behavioral impairments and their neurochemical mechanisms in the MitoPark mouse model of progressive neurodegeneration in Parkinson's disease.
    Langley MR; Ghaisas S; Palanisamy BN; Ay M; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
    Exp Neurol; 2021 Jul; 341():113716. PubMed ID: 33839143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mito-Apocynin Prevents Mitochondrial Dysfunction, Microglial Activation, Oxidative Damage, and Progressive Neurodegeneration in MitoPark Transgenic Mice.
    Langley M; Ghosh A; Charli A; Sarkar S; Ay M; Luo J; Zielonka J; Brenza T; Bennett B; Jin H; Ghaisas S; Schlichtmann B; Kim D; Anantharam V; Kanthasamy A; Narasimhan B; Kalyanaraman B; Kanthasamy AG
    Antioxid Redox Signal; 2017 Nov; 27(14):1048-1066. PubMed ID: 28375739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tetramethylpyrazine Analogue T-006 Exerts Neuroprotective Effects against 6-Hydroxydopamine-Induced Parkinson's Disease
    Zhou H; Shao M; Yang X; Li C; Cui G; Gao C; Di L; Zhong H; Wang Y; Zhang Z; Lee SM
    Oxid Med Cell Longev; 2019; 2019():8169125. PubMed ID: 31827703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotection by neuropeptide Y in cell and animal models of Parkinson's disease.
    Decressac M; Pain S; Chabeauti PY; Frangeul L; Thiriet N; Herzog H; Vergote J; Chalon S; Jaber M; Gaillard A
    Neurobiol Aging; 2012 Sep; 33(9):2125-37. PubMed ID: 21816512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein kinase D1 (PKD1) phosphorylation promotes dopaminergic neuronal survival during 6-OHDA-induced oxidative stress.
    Asaithambi A; Ay M; Jin H; Gosh A; Anantharam V; Kanthasamy A; Kanthasamy AG
    PLoS One; 2014; 9(5):e96947. PubMed ID: 24806360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial biogenesis: pharmacological approaches.
    Valero T
    Curr Pharm Des; 2014; 20(35):5507-9. PubMed ID: 24606795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FLZ protects dopaminergic neuron through activating protein kinase B/mammalian target of rapamycin pathway and inhibiting RTP801 expression in Parkinson's disease models.
    Bao XQ; Kong XC; Qian C; Zhang D
    Neuroscience; 2012 Jan; 202():396-404. PubMed ID: 22138155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AAV.shRNA-mediated downregulation of ROCK2 attenuates degeneration of dopaminergic neurons in toxin-induced models of Parkinson's disease in vitro and in vivo.
    Saal KA; Koch JC; Tatenhorst L; Szegő EM; Ribas VT; Michel U; Bähr M; Tönges L; Lingor P
    Neurobiol Dis; 2015 Jan; 73():150-62. PubMed ID: 25283984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transgenic rodent models of Parkinson's disease.
    Harvey BK; Wang Y; Hoffer BJ
    Acta Neurochir Suppl; 2008; 101():89-92. PubMed ID: 18642640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease.
    Nordströma U; Beauvais G; Ghosh A; Pulikkaparambil Sasidharan BC; Lundblad M; Fuchs J; Joshi RL; Lipton JW; Roholt A; Medicetty S; Feinstein TN; Steiner JA; Escobar Galvis ML; Prochiantz A; Brundin P
    Neurobiol Dis; 2015 Jan; 73():70-82. PubMed ID: 25281317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson's disease model.
    Tasaki Y; Yamamoto J; Omura T; Sakaguchi T; Kimura N; Ohtaki K; Ono T; Suno M; Asari M; Ohkubo T; Noda T; Awaya T; Shimizu K; Matsubara K
    Neurosci Lett; 2012 Jul; 521(1):15-9. PubMed ID: 22617635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of dopamine disrupts circadian rhythms in a mouse model of Parkinson's disease.
    Fifel K; Cooper HM
    Neurobiol Dis; 2014 Nov; 71():359-69. PubMed ID: 25171792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's disease.
    Good CH; Hoffman AF; Hoffer BJ; Chefer VI; Shippenberg TS; Bäckman CM; Larsson NG; Olson L; Gellhaar S; Galter D; Lupica CR
    FASEB J; 2011 Apr; 25(4):1333-44. PubMed ID: 21233488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of robust protective effect of quercetin in two types of 6-hydroxydopamine-induced parkinsonian models in rats and dopaminergic cell cultures.
    Kääriäinen TM; Piltonen M; Ossola B; Kekki H; Lehtonen S; Nenonen T; Lecklin A; Raasmaja A; Männistö PT
    Brain Res; 2008 Apr; 1203():149-59. PubMed ID: 18329008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fyn Kinase Regulates Microglial Neuroinflammatory Responses in Cell Culture and Animal Models of Parkinson's Disease.
    Panicker N; Saminathan H; Jin H; Neal M; Harischandra DS; Gordon R; Kanthasamy K; Lawana V; Sarkar S; Luo J; Anantharam V; Kanthasamy AG; Kanthasamy A
    J Neurosci; 2015 Jul; 35(27):10058-77. PubMed ID: 26157004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.